ARTEMIDE-01

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jun 4, 2023 → Oct 26, 2026

Cited window

Jun 4, 2023 → Aug 14, 2026

Retrieved

Oct 29, 2026

Title

Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Registry

NCT04995523

Study IDs

D7020C00001 · 2023-508262-15-00 (EU CT Number) · 2021-000857-23

Sponsor

AstraZeneca

Design

Phase 1/Phase 2 · Interventional, non randomized, sequential

Status

Active, not recruiting

Enrollment

212 actual

Start

2021-09-14 actual

Primary completion

2026-08-28 estimated

Primary endpoint

Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –2 matching sources (2 X threads) could not be read and are not included.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –20 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are a limited and uneven sample of public discussion; source totals and reposts cannot be interpreted as independent-HCP counts or the prevalence of a view.
• –Some potentially relevant public posts were unavailable or incompletely assessed. Discussion that did not use recognizable trial or drug names may be missing.
• –Several named authors’ clinical roles are not established. Source descriptions of credentials or trial involvement do not independently verify clinical qualifications or make trial-associated views external assessments.
• –The results publication reports CPI-experienced parts A and B. CPI-naive efficacy figures in this report are presented as the figures cited by the relevant commentators, not as findings established by that publication.
• –Comments from different meetings, post dates, treatment-exposure settings and data cutoffs cannot establish a change of mind or a direct efficacy comparison.
• –The patient-facing video leaves contradictory prior-immunotherapy requirements unexplained and does not establish a current arm count.
• –A standalone protocol and an exact AZD2936 regulatory label were not available; no regulatory position is inferred.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "ARTEMIDE-01" (NCT04995523), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "artemide-01-04995523". If you cannot make requests, read https://www.erudio.com/reports/artemide-01-nct04995523.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT04995523", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct04995523 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/artemide-01-nct04995523.json
curl https://www.erudio.com/reports/artemide-01-nct04995523.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "artemide-01-04995523" })